{"gene":"E4F1","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":1987,"finding":"E4F1 (E4F) binds to two sites within the adenovirus E4 enhancer and one site upstream of the E4 TATA box, and this binding is required for constitutive enhancer-driven transcriptional activity in vitro, establishing E4F1 as a direct transcriptional activator of the E4 promoter.","method":"In vitro transcription assay, DNA binding (footprinting/gel shift), mutational analysis of binding sites","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of transcription with defined binding-site mutations, replicated across multiple promoter contexts in the same study","pmids":["2956091"],"is_preprint":false},{"year":1989,"finding":"E4F (E4F1) DNA-binding activity is regulated by phosphorylation: alkaline phosphatase treatment abolishes binding activity, and re-incubation with extract from virus-infected cells restores it. A 50 kDa polypeptide was identified as the E4F factor by affinity purification.","method":"Affinity purification, alkaline phosphatase treatment, in vitro DNA-binding assay","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct biochemical reconstitution (phosphatase treatment + re-activation), single lab with two orthogonal methods (purification + phosphatase assay)","pmids":["2545525"],"is_preprint":false},{"year":1990,"finding":"E4F and ATF recognize the same DNA element in the E4 promoter but differ in sequence specificity (E4F binds only a subset of ATF sites, not E2/E3 promoter ATF sites) and complex stability (E4F forms a stable complex; ATF dissociates rapidly). Only E4F-binding sequences confer E1A inducibility, linking E4F specifically to E1A-dependent trans-activation.","method":"DNA-binding assays (EMSA), cotransfection reporter assays, site-specific mutagenesis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — comparative binding assays with mutagenesis and functional reporter assays, single lab, multiple orthogonal methods","pmids":["2169022"],"is_preprint":false},{"year":1992,"finding":"E1A-dependent activation of the E4 promoter in HeLa cells is primarily mediated through E4F (not ATF-2): carboxy-terminal auxiliary regions (AR1, AR2) of E1A 289R are required for E1A-induced activation of E4F DNA-binding activity but not ATF-2 activity.","method":"Cotransfection reporter assays, E1A deletion mutant analysis","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic (deletion mutant) and reporter assay approaches, single lab","pmids":["1387083"],"is_preprint":false},{"year":1997,"finding":"E4F1 (50 kDa E4F) is the N-terminal fragment of the full-length 783-amino-acid protein (human homolog of murine phiAP3), a GLI-Krüppel zinc-finger protein. E1A(13S) differentially phosphorylates and regulates both forms: it stimulates DNA-binding of the 50 kDa fragment while reducing that of the full-length protein. The full-length protein represses the E4 promoter in the absence of E1A, while the fragment stimulates it in E1A's presence.","method":"Expression cloning, immunological characterization, DNA-binding assays, transient transfection reporter assays, phosphorylation analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — cDNA cloning with immunological verification, biochemical characterization, multiple functional readouts in the same study","pmids":["9121437"],"is_preprint":false},{"year":2004,"finding":"E4F1 is required for mitotic progression during embryonic cell cycles: E4F knockout mice die at peri-implantation, and E4F−/− blastocysts show chromosomal missegregation, defects in mitotic progression, and increased apoptosis. E4F localizes to the mitotic spindle during M phase in early embryos.","method":"Gene targeting (knockout mouse), live-cell imaging/immunofluorescence of spindle localization, flow cytometry for cell cycle analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic knockout with defined mitotic phenotype and direct spindle localization, replicated with multiple readouts","pmids":["15226446"],"is_preprint":false},{"year":2004,"finding":"E4F1 (p120 E4F) physically interacts with RASSF1A in yeast and mammalian cells, forming a complex in vivo, confirmed by in vitro pull-down, in vivo pull-down, and co-immunoprecipitation. RASSF1A knockdown disrupts this interaction. Co-expression of RASSF1A and p120(E4F) enhances G1 arrest and S-phase inhibition.","method":"Yeast two-hybrid, in vitro pull-down, in vivo pull-down, co-immunoprecipitation, siRNA knockdown, flow cytometry (cell cycle)","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP and pull-down, multiple orthogonal binding assays, functional cell cycle readout","pmids":["14729613"],"is_preprint":false},{"year":2006,"finding":"E4F1 is an atypical E3 ubiquitin ligase for p53 that stimulates oligo-ubiquitylation on lysine residues in the hinge region of p53, distinct from Hdm2 target lysines. E4F1-dependent ubiquitylated p53 remains chromatin-associated and promotes a p53-dependent transcriptional program for cell cycle arrest rather than apoptosis. E4F1 and PCAF mediate mutually exclusive post-translational modifications of p53.","method":"In vitro ubiquitylation assay, mass spectrometry (site mapping), chromatin immunoprecipitation (ChIP), reporter assays, cell fate (apoptosis vs. growth arrest) analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro ubiquitylation reconstitution, site mapping by MS, ChIP, and functional cell fate readouts, published in Cell","pmids":["17110336"],"is_preprint":false},{"year":2006,"finding":"E4F1 interacts with BMI1 in hematopoietic cells (co-immunoprecipitation/pulldown), and genetic interaction between Bmi1 and E4f1 regulates cellular proliferation. RNAi-mediated knockdown of E4f1 rescues clonogenic and repopulating ability of Bmi1−/− hematopoietic cells, and this interaction is independent of INK4A/ARF and p53.","method":"Co-immunoprecipitation, RNA interference, hematopoietic transplantation assays, clonogenic assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — physical interaction confirmed by Co-IP plus in vivo genetic rescue experiment in transplantation model","pmids":["16882984"],"is_preprint":false},{"year":2006,"finding":"Full-length E4F1 (p120E4F1), but not its truncated E1A-activated form (p50E4F1), directly interacts with the LIM-only protein FHL2 in vitro and in vivo in the nuclear compartment. This interaction inhibits E4F1's antiproliferative activity and its transcriptional repression, and reduces nuclear E4F1-p53 complexes. FHL2 nuclear accumulation upon UV light promotes endogenous E4F1-FHL2 complex formation.","method":"In vitro binding assay, co-immunoprecipitation, immunofluorescence (localization), reporter assays, UV-light stimulation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vitro binding plus reciprocal Co-IP in cells, functional repression assay, localization data, single lab with multiple orthogonal methods","pmids":["16652157"],"is_preprint":false},{"year":2007,"finding":"E4F1 forms a complex with LANP (an INHAT corepressor) and modulates transcriptional repression. Ataxin 1 competes with E4F1 for LANP binding, thereby relieving the transcriptional repression induced by the LANP-E4F1 complex.","method":"Co-immunoprecipitation, transcriptional reporter assays, competition binding assays","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for complex, reporter assay for function, competition experiment, single lab","pmids":["17557114"],"is_preprint":false},{"year":2010,"finding":"E4F1 is essential for epidermal stem cell (ESC) maintenance and skin homeostasis in vivo. E4F1 conditional knockout in skin causes ESC pool exhaustion. Clonogenic potential of E4F1 KO ESCs is rescued by BMI1 overexpression or by Ink4a/Arf or p53 depletion, placing E4F1 upstream of the BMI1-Arf-p53 pathway in skin stem cells.","method":"Conditional knockout (Cre-loxP), ex vivo clonogenic assays, genetic epistasis (double knockout/overexpression rescue)","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with defined phenotype, epistasis rescue with multiple genetic combinations, in vivo and ex vivo readouts","pmids":["21088222"],"is_preprint":false},{"year":2011,"finding":"E4F1 inactivation in myeloid leukemic (histiocytic sarcoma) cells causes mitochondrial defects, increased reactive oxygen species (ROS) production, and massive autophagic cell death — effects observed in transformed cells but not normal primary macrophages. In vivo, genetic ablation of E4F1 in established tumors causes tumor regression.","method":"Cre-mediated conditional deletion in vivo (genetically engineered mouse model), ROS measurement, mitochondrial function assays, autophagy markers, shRNA knockdown in human cell lines","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic deletion with tumor regression, mechanistic mitochondrial/ROS assays, validated in human cell lines","pmids":["21708927"],"is_preprint":false},{"year":2013,"finding":"E4F1 physically interacts with hepatitis B virus protein HBx (co-precipitation in HCC cell lines). E4F1 depletion in HBV-expressing (but not HBV-negative) HCC cells induces hepatocyte vacuolation, increased autophagy, mitochondrial defects, and G1 cell cycle arrest; these effects are partially prevented by siRNA against HBx or p53.","method":"Co-immunoprecipitation/co-precipitation, RNA interference, flow cytometry (cell cycle), autophagy assays, metabolic profiling","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP for interaction, RNAi for functional readouts in HBV-dependent context, single lab with multiple readouts","pmids":["24163401"],"is_preprint":false},{"year":2015,"finding":"E4F1 directly controls transcription of Chek1 (CHK1) and genes involved in mitochondrial function. E4F1 inactivation in p53-deficient transformed cells causes CHK1-dependent checkpoint deficiency combined with mitochondrial dysfunction (increased ROS, energy stress, inhibition of de novo pyrimidine synthesis), leading to cell death. E4F1 ChIP-seq identified direct genomic targets in MEFs.","method":"ChIP-seq, RNA-seq (differential expression in E4F1 KO vs. WT), conditional knockout, ROS/metabolic assays, cell death assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP-seq establishes direct binding at Chek1 locus, combined with transcriptomic and metabolic functional readouts in KO model","pmids":["25843721"],"is_preprint":false},{"year":2015,"finding":"E4F1 physically interacts with CHK1 protein and protects it from degradation, functioning as a master regulator of CHK1. E4f1-deficient hematopoietic cells accumulate DNA damage, show S-phase and mitotic progression defects, and undergo apoptosis; ectopic Chek1 expression fully rescues these defects.","method":"Co-immunoprecipitation, conditional knockout (Cre-loxP in hematopoietic cells), DNA damage assays, cell cycle analysis, Chek1 overexpression rescue","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP plus full genetic rescue by Chek1 overexpression, in vivo knockout with defined phenotype, two independent labs (Sauvageau and Grote groups)","pmids":["25843717"],"is_preprint":false},{"year":2016,"finding":"E4F1 transcriptionally regulates four genes (Dlat, Dld, Mpc1, Slc25a19) required for pyruvate oxidation; E4F1 dysfunction results in ~80% decrease in pyruvate dehydrogenase (PDH) complex activity and altered pyruvate metabolism. Muscle-specific E4f1 knockout mice show low PDH activity, severe endurance defects, and chronic lactic acidemia.","method":"ChIP (direct binding to target gene promoters), conditional knockout (muscle-specific), PDH activity assay, metabolic profiling, pharmacological PDH stimulation and ketogenic diet rescue","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct ChIP binding plus enzymatic assay in KO tissue, pharmacological rescue, confirmed in two complementary PNAS studies (PMID 27621446 and 27621431)","pmids":["27621446","27621431"],"is_preprint":false},{"year":2016,"finding":"In keratinocytes, E4F1 transcriptionally regulates Dlat (encoding the E2 subunit of the PDH complex); E4f1 KO keratinocytes show impaired PDH activity, redirected glycolytic flux toward lactate, extracellular matrix remodeling, and loss of clonogenic potential. shRNA depletion of Dlat alone recapitulates these defects.","method":"Conditional knockout, PDH activity assay, metabolic flux assay (lactate measurement), shRNA knockdown, clonogenic assay","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with mechanistic PDH activity readout, shRNA validation of Dlat as key effector, multiple orthogonal metabolic assays","pmids":["27621431"],"is_preprint":false},{"year":2020,"finding":"The 50 kDa form of E4F1 (p50E4F1) stably associates with E1A289R in vivo via the p50E4F1 transcription regulatory (TR) region and E1A CR3. E1A-mediated trans-activation requires the p50E4F1 TR region to be promoter-bound and depends on E1A CR3, CR1, and N-terminal domains. Multiple cellular proteins including TBP bind the p50E4F1 TR region in vitro.","method":"In vivo co-immunoprecipitation, in vitro binding assays, GAL4-fusion trans-activation assays, deletion mutagenesis","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — in vivo and in vitro binding with mutagenesis and functional trans-activation reporter assays, single lab","pmids":["32535047"],"is_preprint":false},{"year":2021,"finding":"E4F1 promotes DNA double-strand break (DSB) repair by: (1) being recruited to DNA breaks in a PARP-dependent manner; (2) promoting ATR/CHK1 signaling and DNA-end resection for homologous recombination; (3) binding to the chromatin remodeler BRG1/SMARCA4 and together with PARP-1 mediating BRG1 recruitment to DNA lesions.","method":"Live-cell imaging (recruitment to DNA breaks), PARP inhibitor treatment, co-immunoprecipitation (E4F1-BRG1), HR repair assays, DNA resection assays, CHK1 signaling assays","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Co-IP, live imaging, PARP-dependence, HR assays), mechanistic pathway placement, published in PNAS","pmids":["33692124"],"is_preprint":false},{"year":2021,"finding":"E4F1 directly interacts with p53 and both co-occupy the Stearoyl-CoA Desaturase-1 (SCD1) locus in adipocytes to regulate monounsaturated fatty acid synthesis. E4F1 deficiency in adipose tissue activates a p53-dependent transcriptional program controlling lipid metabolism; p53 inactivation or oleate supplementation partially restores adiposity in E4F1-deficient mice.","method":"ChIP (E4F1 and p53 co-occupancy at SCD1 locus), co-immunoprecipitation (E4F1-p53 interaction), conditional adipose-specific knockout, metabolic phenotyping, genetic epistasis (p53 inactivation rescue)","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct ChIP for co-occupancy at specific locus, Co-IP for interaction, in vivo KO with genetic rescue by p53 deletion, multiple orthogonal methods","pmids":["34857760"],"is_preprint":false},{"year":2022,"finding":"In triple-negative breast cancer (TNBC) cells, E4F1 directly binds and regulates CHEK1 and two additional post-transcriptional regulators of the ATM/ATR-CHK1 axis: TTI2 (TTT complex, required for ATM/ATR folding/stability) and PPP5C (phosphatase regulating ATM/ATR signaling). E4F1 depletion downregulates CHK1, ATM, and ATR protein levels and signaling, causing failure to arrest in S-phase upon Gemcitabine treatment and sensitization to DNA-damaging agents.","method":"ChIP-seq, RNA-seq, E4F1 depletion (shRNA/siRNA), ATM/ATR/CHK1 signaling assays, PDX ChIP validation, drug sensitivity assays","journal":"International journal of molecular sciences","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP-seq with RNA-seq intersection identifies direct targets, PDX in vivo validation, mechanistic signaling readouts, single lab","pmids":["36012478"],"is_preprint":false},{"year":2023,"finding":"E4F1 binds specifically to the -57A>C mutant TERT promoter and activates TERT transcription and telomerase activity. ZNF148 binds the wild-type TERT promoter and is a separate activating factor. Both were identified by a systematic proteomics screen (SILAC-based pull-down) and validated by ChIP in corresponding cell lines.","method":"SILAC-based proteomics pull-down screen, ChIP, TERT reporter assay, telomerase activity assay","journal":"Genome research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomics pull-down discovery plus ChIP and functional reporter validation, single lab","pmids":["37918959"],"is_preprint":false},{"year":2024,"finding":"In human cells, NF-κB/RelA cooperates with E4F1 to regulate dynamic expression of hsa-miR-210 during TLR immune responses, mirroring a conserved mechanism where Dorsal cooperates with Su(Hw) in Drosophila.","method":"Co-immunoprecipitation (RelA-E4F1), reporter assays, miR-210 expression assays upon TLR stimulation, knockdown experiments","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP for interaction plus functional reporter data in human cells, single lab","pmids":["38742642"],"is_preprint":false},{"year":2025,"finding":"E4F1 directly transcriptionally regulates both Dlat (PDH complex E2 subunit) and Elp3 (catalytic subunit of the Elongator complex) in neurons, coordinating AcCoA production by PDC and its utilization by Elongator to acetylate tRNAs at wobble uridine 34 (U34). This E4F1-mediated coordination ensures translation fidelity and neuronal cell survival during brain development. PDH-deficient (Leigh syndrome) cells show a perturbed PDC-to-ELP3 crosstalk.","method":"Conditional knockout (mouse), ChIP (direct promoter binding), primary neuronal cell assays, tRNA acetylation assay, translation fidelity assay, PDH-deficient patient cell analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct ChIP for dual target gene binding, in vivo KO with neuronal phenotype, biochemical tRNA acetylation and translation fidelity readouts, disease-relevant validation","pmids":["39747033"],"is_preprint":false}],"current_model":"E4F1 is a multifunctional GLI-Krüppel zinc-finger transcription factor and atypical E3 ubiquitin ligase that: (1) directly binds specific promoter elements to activate or repress transcription; (2) oligo-ubiquitylates p53 on hinge-region lysines (distinct from Hdm2 sites) to promote chromatin-associated p53-dependent cell cycle arrest rather than apoptosis; (3) transcriptionally controls a metabolic gene program encompassing the pyruvate dehydrogenase complex (Dlat, Dld, Mpc1, Slc25a19) and the Elongator complex (Elp3) to coordinate AcCoA production, tRNA acetylation, and translation fidelity; (4) regulates ATR/CHK1 signaling by directly driving CHEK1, TTI2, and PPP5C transcription and by physically protecting CHK1 from degradation; (5) is recruited to DNA double-strand breaks in a PARP-dependent manner, promotes DNA-end resection and homologous recombination via interaction with BRG1/SMARCA4; (6) interacts with multiple partners including BMI1, RASSF1A, FHL2, LANP/ataxin 1, and p53 to control stem cell maintenance, hematopoiesis, and cell fate decisions."},"narrative":{"mechanistic_narrative":"E4F1 is a multifunctional GLI-Krüppel zinc-finger transcription factor that controls cell cycle progression, metabolism, and genome stability, and was originally defined as a direct, sequence-specific activator of the adenovirus E4 promoter whose DNA-binding is phosphorylation-dependent and inducible by E1A [PMID:2956091, PMID:2545525, PMID:9121437]. The protein exists as a full-length form (p120E4F1) that represses transcription and an E1A-activated N-terminal 50 kDa fragment (p50E4F1) that stimulates it, the latter associating with E1A and basal factors such as TBP through its transcription regulatory region [PMID:9121437, PMID:32535047]. Beyond transcription, E4F1 acts as an atypical E3 ubiquitin ligase that oligo-ubiquitylates p53 on hinge-region lysines distinct from Hdm2 sites, retaining p53 on chromatin to drive a cell cycle arrest program rather than apoptosis [PMID:17110336]. E4F1 is required for mitotic fidelity in vivo, where its loss causes chromosomal missegregation and embryonic lethality [PMID:15226446]. It governs a transcriptional metabolic program by directly binding and activating pyruvate dehydrogenase complex genes (Dlat, Dld, Mpc1, Slc25a19), with loss causing collapsed PDH activity, lactic acidemia, and metabolic stress [PMID:27621446, PMID:27621431]; in neurons it co-regulates Dlat and the Elongator subunit Elp3 to couple AcCoA production to wobble-U34 tRNA acetylation and translation fidelity [PMID:39747033]. E4F1 is also a master regulator of the ATR/CHK1 DNA-damage axis, directly driving CHEK1 (and the regulators TTI2 and PPP5C) transcription and physically binding CHK1 to protect it from degradation [PMID:25843721, PMID:25843717, PMID:36012478], and it is recruited to double-strand breaks in a PARP-dependent manner to promote end resection and homologous recombination via the chromatin remodeler BRG1/SMARCA4 [PMID:33692124]. Through physical interactions with BMI1, RASSF1A, FHL2, and p53, E4F1 integrates these activities into control of stem cell maintenance, hematopoiesis, and tumor cell survival [PMID:14729613, PMID:16882984, PMID:16652157, PMID:21088222, PMID:34857760].","teleology":[{"year":1987,"claim":"Established that E4F1 is a bona fide sequence-specific transcriptional activator, defining its founding molecular activity by showing its binding sites are required for E4 enhancer-driven transcription.","evidence":"In vitro transcription and DNA footprinting/gel-shift with binding-site mutants on the adenovirus E4 promoter","pmids":["2956091"],"confidence":"High","gaps":["Did not identify the cellular gene targets beyond the viral E4 promoter","No structural basis for sequence recognition"]},{"year":1989,"claim":"Showed that E4F1 DNA-binding is post-translationally controlled by phosphorylation and identified the factor as a ~50 kDa polypeptide, linking its activity to signaling.","evidence":"Affinity purification with alkaline phosphatase treatment and in vitro DNA-binding reactivation by infected-cell extract","pmids":["2545525"],"confidence":"High","gaps":["Kinase responsible not identified","Phosphorylation sites not mapped"]},{"year":1990,"claim":"Distinguished E4F1 from ATF in binding specificity and complex stability and tied E4F1 specifically to E1A-dependent trans-activation, clarifying the functional element it controls.","evidence":"Comparative EMSA, site-specific mutagenesis, and cotransfection reporter assays","pmids":["2169022"],"confidence":"High","gaps":["Molecular basis of differential complex stability unresolved","Cellular promoters obeying the same code unidentified"]},{"year":1997,"claim":"Cloned the full-length 783-aa GLI-Krüppel protein and showed the 50 kDa species is an N-terminal fragment, revealing that full-length p120 represses while the p50 fragment activates, and that E1A differentially regulates the two forms.","evidence":"Expression cloning, immunological characterization, DNA-binding and reporter assays with phosphorylation analysis","pmids":["9121437"],"confidence":"High","gaps":["Mechanism generating the p50 fragment in cells not defined","Domain map of repression vs activation incomplete"]},{"year":2004,"claim":"Demonstrated an essential in vivo cell-cycle function: E4F1 is required for mitotic progression and chromosome segregation, with spindle localization, moving it from a viral cofactor to a core cell-cycle regulator.","evidence":"Knockout mouse with blastocyst analysis, spindle immunofluorescence, and flow cytometry","pmids":["15226446"],"confidence":"High","gaps":["Molecular targets driving the mitotic defect not identified","Whether spindle localization reflects a non-transcriptional role unresolved"]},{"year":2004,"claim":"Identified RASSF1A as a physical partner that cooperates with E4F1 to enforce G1/S arrest, placing E4F1 in a tumor-suppressor interaction network.","evidence":"Yeast two-hybrid, reciprocal pull-down and Co-IP, siRNA, and cell-cycle flow cytometry","pmids":["14729613"],"confidence":"High","gaps":["Mechanistic consequence of the complex on E4F1 targets unclear","Interaction domains not mapped"]},{"year":2006,"claim":"Revealed an enzymatic activity beyond transcription: E4F1 oligo-ubiquitylates p53 at hinge lysines distinct from Hdm2, channeling p53 toward chromatin-associated arrest rather than apoptosis.","evidence":"In vitro ubiquitylation, MS site mapping, ChIP, and apoptosis-versus-arrest cell-fate readouts","pmids":["17110336"],"confidence":"High","gaps":["The E2 enzyme and full ligase complex not defined","How ubiquitylation directs p53 to specific gene programs unresolved"]},{"year":2006,"claim":"Placed E4F1 in the BMI1 axis controlling hematopoietic proliferation independent of INK4A/ARF and p53, showing E4f1 knockdown rescues Bmi1-deficient stem cells.","evidence":"Co-IP, RNAi, and hematopoietic transplantation/clonogenic assays","pmids":["16882984"],"confidence":"High","gaps":["The p53/INK4A-independent effector pathway not identified","Direct genomic targets in hematopoietic cells unmapped"]},{"year":2006,"claim":"Identified FHL2 as a nuclear inhibitor of full-length E4F1 that dampens its antiproliferative and repressive activity and reduces E4F1-p53 complexes in response to UV.","evidence":"In vitro binding, reciprocal Co-IP, immunofluorescence, and repression reporter assays","pmids":["16652157"],"confidence":"High","gaps":["Whether FHL2 affects E4F1 ligase activity not tested","Physiological signals beyond UV not explored"]},{"year":2007,"claim":"Showed E4F1 acts as a corepressor partner of LANP/INHAT, with ataxin-1 competing for LANP to relieve repression, linking E4F1 to chromatin-based repression machinery.","evidence":"Co-IP, competition binding, and transcriptional reporter assays","pmids":["17557114"],"confidence":"Medium","gaps":["Endogenous target genes of the LANP-E4F1 complex not defined","Single-lab finding without independent reconstitution"]},{"year":2010,"claim":"Established E4F1 as essential for epidermal stem cell maintenance and positioned it upstream of the BMI1-Arf-p53 pathway in skin homeostasis.","evidence":"Conditional skin knockout, ex vivo clonogenic assays, and genetic epistasis rescues","pmids":["21088222"],"confidence":"High","gaps":["Direct transcriptional targets in stem cells not identified","Mechanism linking E4F1 to the BMI1-Arf-p53 axis unresolved at the gene level"]},{"year":2011,"claim":"Revealed a selective dependency of transformed cells on E4F1: its loss triggers mitochondrial dysfunction, ROS, and autophagic death in tumor cells but not normal macrophages, with tumor regression in vivo.","evidence":"Conditional deletion in a mouse tumor model, ROS and mitochondrial assays, and shRNA in human lines","pmids":["21708927"],"confidence":"High","gaps":["The transcriptional targets producing the mitochondrial defect not yet defined here","Basis of tumor-selective dependence unclear"]},{"year":2013,"claim":"Extended the tumor-selective dependency to HBV-positive hepatocellular carcinoma via an E4F1-HBx interaction, with E4F1 loss causing autophagy, mitochondrial defects, and G1 arrest in an HBV/p53-dependent manner.","evidence":"Co-precipitation, RNAi, cell-cycle and autophagy assays in HCC lines","pmids":["24163401"],"confidence":"Medium","gaps":["Functional consequence of the HBx interaction on E4F1 activity not defined","Single-lab, context-restricted finding"]},{"year":2015,"claim":"Connected E4F1 to the DNA-damage checkpoint by both directly transcribing Chek1 and protecting CHK1 protein from degradation, with Chek1 re-expression fully rescuing E4f1-loss phenotypes.","evidence":"ChIP-seq, conditional knockout, Co-IP, DNA-damage/cell-cycle assays, and Chek1 overexpression rescue (two independent labs)","pmids":["25843721","25843717"],"confidence":"High","gaps":["Mechanism by which E4F1 stabilizes CHK1 protein not defined","Coupling between the checkpoint and metabolic roles unresolved"]},{"year":2016,"claim":"Defined E4F1 as a direct transcriptional controller of the pyruvate-oxidation program (Dlat, Dld, Mpc1, Slc25a19), establishing its central role in metabolic gene regulation with in vivo PDH and endurance phenotypes.","evidence":"ChIP, muscle- and keratinocyte-specific knockouts, PDH activity and metabolic flux assays, shRNA of Dlat, and dietary/pharmacological rescue","pmids":["27621446","27621431"],"confidence":"High","gaps":["How metabolic and checkpoint target programs are co-selected unresolved","Upstream signals tuning this program not identified"]},{"year":2021,"claim":"Showed E4F1 is recruited to double-strand breaks in a PARP-dependent manner and promotes end resection and homologous recombination through BRG1/SMARCA4, adding a direct chromatin-level repair function.","evidence":"Live-cell imaging of recruitment, PARP inhibition, Co-IP with BRG1, and HR/resection assays","pmids":["33692124"],"confidence":"High","gaps":["Whether transcriptional and recruitment roles act in parallel at breaks unresolved","Residues mediating PARP-dependent recruitment not mapped"]},{"year":2021,"claim":"Demonstrated direct E4F1-p53 co-occupancy at the SCD1 locus controlling monounsaturated fatty acid synthesis in adipose tissue, broadening the metabolic program to lipid metabolism with p53-dependent rescue.","evidence":"ChIP co-occupancy, Co-IP, adipose-specific knockout, metabolic phenotyping, and p53-deletion/oleate rescue","pmids":["34857760"],"confidence":"High","gaps":["Whether E4F1 ubiquitylation of p53 contributes at this locus untested","Tissue specificity of the SCD1 program unexplained"]},{"year":2022,"claim":"Generalized the ATR/CHK1 axis control to human TNBC, showing E4F1 directly regulates CHEK1, TTI2, and PPP5C and that its loss collapses ATM/ATR/CHK1 signaling and sensitizes cells to DNA-damaging agents.","evidence":"ChIP-seq, RNA-seq, E4F1 depletion, signaling assays, PDX ChIP validation, and drug-sensitivity assays","pmids":["36012478"],"confidence":"High","gaps":["Single-lab finding","Relative contribution of each target to checkpoint failure not dissected"]},{"year":2023,"claim":"Identified E4F1 as a mutation-specific activator of the -57A>C TERT promoter, implicating it in telomerase reactivation in cancer.","evidence":"SILAC pull-down proteomics screen, ChIP, TERT reporter, and telomerase activity assays","pmids":["37918959"],"confidence":"Medium","gaps":["Why E4F1 selectively binds the mutant promoter not defined","Single-lab proteomics-based discovery"]},{"year":2024,"claim":"Showed E4F1 cooperates with NF-κB/RelA to control dynamic miR-210 expression during TLR immune responses, extending its transcriptional partnerships to innate immunity.","evidence":"RelA-E4F1 Co-IP, reporter assays, and miR-210 expression upon TLR stimulation with knockdowns","pmids":["38742642"],"confidence":"Medium","gaps":["Direct binding of E4F1 at the miR-210 locus in human cells not fully resolved","Physiological immune consequence untested"]},{"year":2025,"claim":"Revealed that E4F1 coordinates AcCoA production (via Dlat/PDC) with its utilization by the Elongator subunit Elp3 for wobble-U34 tRNA acetylation, linking metabolism to translation fidelity and neuronal survival.","evidence":"Conditional knockout, ChIP at Dlat and Elp3, tRNA acetylation and translation-fidelity assays, and PDH-deficient patient cell analysis","pmids":["39747033"],"confidence":"High","gaps":["How E4F1 simultaneously sets producer and consumer gene levels mechanistically unresolved","Generality of the PDC-Elongator crosstalk beyond neurons untested"]},{"year":null,"claim":"It remains unresolved how E4F1 integrates its dual roles as a transcription factor and an atypical p53 E3 ligase, and what signals partition it between metabolic, checkpoint, and DNA-repair programs in a given cell type.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model coordinating DNA-binding and ligase domains","Mechanism stabilizing CHK1 protein undefined","Rules selecting metabolic vs checkpoint target genes unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,4]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,4,14,16,24]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[7]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[7]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[23]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[9]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[7,19]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,4,14,16,24]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[5,6,15]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[19,21]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[14,15,21]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[16,17,20,24]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[7]}],"complexes":[],"partners":["TP53","BMI1","RASSF1A","FHL2","CHEK1","SMARCA4","RELA"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q66K89","full_name":"Transcription factor E4F1","aliases":["E4F transcription factor 1","Putative E3 ubiquitin-protein ligase E4F1","RING-type E3 ubiquitin transferase E4F1","Transcription factor E4F","p120E4F","p50E4F"],"length_aa":784,"mass_kda":83.5,"function":"May function as a transcriptional repressor. May also function as a ubiquitin ligase mediating ubiquitination of chromatin-associated TP53. Functions in cell survival and proliferation through control of the cell cycle. Functions in the p53 and pRB tumor suppressor pathways and regulates the cyclin CCNA2 transcription Identified as a cellular target of the adenoviral oncoprotein E1A, it is required for both transcriptional activation and repression of viral genes","subcellular_location":"Nucleus, nucleoplasm; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q66K89/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/E4F1","classification":"Common Essential","n_dependent_lines":589,"n_total_lines":1208,"dependency_fraction":0.48758278145695366},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/E4F1","total_profiled":1310},"omim":[{"mim_id":"605082","title":"RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1; RASSF1","url":"https://www.omim.org/entry/605082"},{"mim_id":"603022","title":"E4F TRANSCRIPTION FACTOR 1; E4F1","url":"https://www.omim.org/entry/603022"},{"mim_id":"191170","title":"TUMOR PROTEIN p53; TP53","url":"https://www.omim.org/entry/191170"},{"mim_id":"164831","title":"BMI1 PROTOONCOGENE, POLYCOMB RING FINGER; BMI1","url":"https://www.omim.org/entry/164831"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/E4F1"},"hgnc":{"alias_symbol":["E4F"],"prev_symbol":[]},"alphafold":{"accession":"Q66K89","domains":[{"cath_id":"3.30.160.60","chopping":"186-271","consensus_level":"medium","plddt":79.3426,"start":186,"end":271},{"cath_id":"-","chopping":"628-646_656-695_710-732","consensus_level":"high","plddt":62.7438,"start":628,"end":732}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q66K89","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q66K89-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q66K89-F1-predicted_aligned_error_v6.png","plddt_mean":52.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=E4F1","jax_strain_url":"https://www.jax.org/strain/search?query=E4F1"},"sequence":{"accession":"Q66K89","fasta_url":"https://rest.uniprot.org/uniprotkb/Q66K89.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q66K89/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q66K89"}},"corpus_meta":[{"pmid":"2956091","id":"PMC_2956091","title":"A cellular transcription factor E4F1 interacts with an E1a-inducible enhancer and mediates constitutive enhancer function in vitro.","date":"1987","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2956091","citation_count":184,"is_preprint":false},{"pmid":"17110336","id":"PMC_17110336","title":"E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17110336","citation_count":181,"is_preprint":false},{"pmid":"2545525","id":"PMC_2545525","title":"DNA-binding activity of the adenovirus-induced E4F transcription factor is regulated by phosphorylation.","date":"1989","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/2545525","citation_count":100,"is_preprint":false},{"pmid":"35340126","id":"PMC_35340126","title":"m6A hypomethylation of DNMT3B regulated by ALKBH5 promotes intervertebral disc degeneration via E4F1 deficiency.","date":"2022","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35340126","citation_count":62,"is_preprint":false},{"pmid":"14729613","id":"PMC_14729613","title":"Identification of the E1A-regulated transcription factor p120 E4F as an interacting partner of the RASSF1A candidate tumor suppressor gene.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14729613","citation_count":62,"is_preprint":false},{"pmid":"15226446","id":"PMC_15226446","title":"The E4F protein is required for mitotic progression during embryonic cell cycles.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15226446","citation_count":49,"is_preprint":false},{"pmid":"16882984","id":"PMC_16882984","title":"E4F1: a novel candidate factor for mediating BMI1 function in primitive hematopoietic cells.","date":"2006","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/16882984","citation_count":47,"is_preprint":false},{"pmid":"2169022","id":"PMC_2169022","title":"E4F and ATF, two transcription factors that recognize the same site, can be distinguished both physically and functionally: a role for E4F in E1A trans activation.","date":"1990","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2169022","citation_count":40,"is_preprint":false},{"pmid":"25843721","id":"PMC_25843721","title":"The transcription factor E4F1 coordinates CHK1-dependent checkpoint and mitochondrial functions.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25843721","citation_count":39,"is_preprint":false},{"pmid":"17557114","id":"PMC_17557114","title":"The role of LANP and ataxin 1 in E4F-mediated transcriptional repression.","date":"2007","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/17557114","citation_count":38,"is_preprint":false},{"pmid":"16652157","id":"PMC_16652157","title":"The LIM-only protein FHL2 is a negative regulator of E4F1.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16652157","citation_count":37,"is_preprint":false},{"pmid":"21088222","id":"PMC_21088222","title":"Transcription factor E4F1 is essential for epidermal stem cell maintenance and skin homeostasis.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21088222","citation_count":35,"is_preprint":false},{"pmid":"27621446","id":"PMC_27621446","title":"E4F1 controls a transcriptional program essential for pyruvate dehydrogenase activity.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27621446","citation_count":35,"is_preprint":false},{"pmid":"9121437","id":"PMC_9121437","title":"The adenovirus E1A-regulated transcription factor E4F is generated from the human homolog of nuclear factor phiAP3.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9121437","citation_count":33,"is_preprint":false},{"pmid":"33692124","id":"PMC_33692124","title":"Zinc finger protein E4F1 cooperates with PARP-1 and BRG1 to promote DNA double-strand break repair.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33692124","citation_count":32,"is_preprint":false},{"pmid":"27621431","id":"PMC_27621431","title":"E4F1-mediated control of pyruvate dehydrogenase activity is essential for skin homeostasis.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27621431","citation_count":30,"is_preprint":false},{"pmid":"1387083","id":"PMC_1387083","title":"The carboxy-terminal exon of the adenovirus E1A protein is required for E4F-dependent transcription activation.","date":"1992","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/1387083","citation_count":29,"is_preprint":false},{"pmid":"1831536","id":"PMC_1831536","title":"E1A-mediated activation of the adenovirus E4 promoter can occur independently of the cellular transcription factor E4F.","date":"1991","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1831536","citation_count":22,"is_preprint":false},{"pmid":"21708927","id":"PMC_21708927","title":"E4F1 deficiency results in oxidative stress-mediated cell death of leukemic cells.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21708927","citation_count":21,"is_preprint":false},{"pmid":"25843717","id":"PMC_25843717","title":"E4F1 is a master regulator of CHK1-mediated functions.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25843717","citation_count":21,"is_preprint":false},{"pmid":"34857760","id":"PMC_34857760","title":"The multifunctional protein E4F1 links P53 to lipid metabolism in adipocytes.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34857760","citation_count":16,"is_preprint":false},{"pmid":"31249647","id":"PMC_31249647","title":"MicroRNA-33-3p Regulates Vein Endothelial Cell Apoptosis in Selenium-Deficient Broilers by Targeting E4F1.","date":"2019","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/31249647","citation_count":16,"is_preprint":false},{"pmid":"37749649","id":"PMC_37749649","title":"Transcription factor E4F1 dictates spermatogonial stem cell fate decisions by regulating mitochondrial functions and cell cycle progression.","date":"2023","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/37749649","citation_count":11,"is_preprint":false},{"pmid":"32962114","id":"PMC_32962114","title":"E4 Transcription Factor 1 (E4F1) Regulates Sertoli Cell Proliferation and Fertility in Mice.","date":"2020","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/32962114","citation_count":10,"is_preprint":false},{"pmid":"22024746","id":"PMC_22024746","title":"E4F1 dysfunction results in autophagic cell death in myeloid leukemic cells.","date":"2011","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/22024746","citation_count":10,"is_preprint":false},{"pmid":"24163401","id":"PMC_24163401","title":"Downregulation of transcription factor E4F1 in hepatocarcinoma cells: HBV-dependent effects on autophagy, proliferation and metabolism.","date":"2013","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24163401","citation_count":10,"is_preprint":false},{"pmid":"26484288","id":"PMC_26484288","title":"Description of an optimized ChIP-seq analysis pipeline dedicated to genome wide identification of E4F1 binding sites in primary and transformed MEFs.","date":"2015","source":"Genomics data","url":"https://pubmed.ncbi.nlm.nih.gov/26484288","citation_count":10,"is_preprint":false},{"pmid":"38742642","id":"PMC_38742642","title":"NF-κB factors cooperate with Su(Hw)/E4F1 to balance Drosophila/human immune responses via modulating dynamic expression of miR-210.","date":"2024","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/38742642","citation_count":9,"is_preprint":false},{"pmid":"33618227","id":"PMC_33618227","title":"Angiotensin II promotes EMT of hepatocellular carcinoma cells through high mobility group protein B1 mediated by E4F1.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33618227","citation_count":8,"is_preprint":false},{"pmid":"30506647","id":"PMC_30506647","title":"E4F1 silencing inhibits the cell growth through cell-cycle arrest in malignant transformed cells induced by hydroquinone.","date":"2018","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/30506647","citation_count":7,"is_preprint":false},{"pmid":"37774036","id":"PMC_37774036","title":"Transcription factor E4F1 as a regulator of cell life and disease progression.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37774036","citation_count":6,"is_preprint":false},{"pmid":"36012478","id":"PMC_36012478","title":"Multi-Level Control of the ATM/ATR-CHK1 Axis by the Transcription Factor E4F1 in Triple-Negative Breast Cancer.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36012478","citation_count":5,"is_preprint":false},{"pmid":"37918959","id":"PMC_37918959","title":"E4F1 and ZNF148 are transcriptional activators of the -57A > C and wild-type TERT promoter.","date":"2023","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/37918959","citation_count":3,"is_preprint":false},{"pmid":"39747033","id":"PMC_39747033","title":"E4F1 coordinates pyruvate metabolism and the activity of the elongator complex to ensure translation fidelity during brain development.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39747033","citation_count":1,"is_preprint":false},{"pmid":"32535047","id":"PMC_32535047","title":"Multiple domains in the 50 kDa form of E4F1 regulate promoter-specific repression and E1A trans-activation.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32535047","citation_count":0,"is_preprint":false},{"pmid":"41981464","id":"PMC_41981464","title":"The transcription factor E4F1 is crucial for spermatogonial differentiation and meiosis progression in mice.","date":"2026","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/41981464","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":18314,"output_tokens":6633,"usd":0.077218,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15520,"output_tokens":6385,"usd":0.118612,"stage2_stop_reason":"end_turn"},"total_usd":0.19583,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1987,\n      \"finding\": \"E4F1 (E4F) binds to two sites within the adenovirus E4 enhancer and one site upstream of the E4 TATA box, and this binding is required for constitutive enhancer-driven transcriptional activity in vitro, establishing E4F1 as a direct transcriptional activator of the E4 promoter.\",\n      \"method\": \"In vitro transcription assay, DNA binding (footprinting/gel shift), mutational analysis of binding sites\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of transcription with defined binding-site mutations, replicated across multiple promoter contexts in the same study\",\n      \"pmids\": [\"2956091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"E4F (E4F1) DNA-binding activity is regulated by phosphorylation: alkaline phosphatase treatment abolishes binding activity, and re-incubation with extract from virus-infected cells restores it. A 50 kDa polypeptide was identified as the E4F factor by affinity purification.\",\n      \"method\": \"Affinity purification, alkaline phosphatase treatment, in vitro DNA-binding assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct biochemical reconstitution (phosphatase treatment + re-activation), single lab with two orthogonal methods (purification + phosphatase assay)\",\n      \"pmids\": [\"2545525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"E4F and ATF recognize the same DNA element in the E4 promoter but differ in sequence specificity (E4F binds only a subset of ATF sites, not E2/E3 promoter ATF sites) and complex stability (E4F forms a stable complex; ATF dissociates rapidly). Only E4F-binding sequences confer E1A inducibility, linking E4F specifically to E1A-dependent trans-activation.\",\n      \"method\": \"DNA-binding assays (EMSA), cotransfection reporter assays, site-specific mutagenesis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — comparative binding assays with mutagenesis and functional reporter assays, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"2169022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"E1A-dependent activation of the E4 promoter in HeLa cells is primarily mediated through E4F (not ATF-2): carboxy-terminal auxiliary regions (AR1, AR2) of E1A 289R are required for E1A-induced activation of E4F DNA-binding activity but not ATF-2 activity.\",\n      \"method\": \"Cotransfection reporter assays, E1A deletion mutant analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (deletion mutant) and reporter assay approaches, single lab\",\n      \"pmids\": [\"1387083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"E4F1 (50 kDa E4F) is the N-terminal fragment of the full-length 783-amino-acid protein (human homolog of murine phiAP3), a GLI-Krüppel zinc-finger protein. E1A(13S) differentially phosphorylates and regulates both forms: it stimulates DNA-binding of the 50 kDa fragment while reducing that of the full-length protein. The full-length protein represses the E4 promoter in the absence of E1A, while the fragment stimulates it in E1A's presence.\",\n      \"method\": \"Expression cloning, immunological characterization, DNA-binding assays, transient transfection reporter assays, phosphorylation analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — cDNA cloning with immunological verification, biochemical characterization, multiple functional readouts in the same study\",\n      \"pmids\": [\"9121437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"E4F1 is required for mitotic progression during embryonic cell cycles: E4F knockout mice die at peri-implantation, and E4F−/− blastocysts show chromosomal missegregation, defects in mitotic progression, and increased apoptosis. E4F localizes to the mitotic spindle during M phase in early embryos.\",\n      \"method\": \"Gene targeting (knockout mouse), live-cell imaging/immunofluorescence of spindle localization, flow cytometry for cell cycle analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic knockout with defined mitotic phenotype and direct spindle localization, replicated with multiple readouts\",\n      \"pmids\": [\"15226446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"E4F1 (p120 E4F) physically interacts with RASSF1A in yeast and mammalian cells, forming a complex in vivo, confirmed by in vitro pull-down, in vivo pull-down, and co-immunoprecipitation. RASSF1A knockdown disrupts this interaction. Co-expression of RASSF1A and p120(E4F) enhances G1 arrest and S-phase inhibition.\",\n      \"method\": \"Yeast two-hybrid, in vitro pull-down, in vivo pull-down, co-immunoprecipitation, siRNA knockdown, flow cytometry (cell cycle)\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP and pull-down, multiple orthogonal binding assays, functional cell cycle readout\",\n      \"pmids\": [\"14729613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"E4F1 is an atypical E3 ubiquitin ligase for p53 that stimulates oligo-ubiquitylation on lysine residues in the hinge region of p53, distinct from Hdm2 target lysines. E4F1-dependent ubiquitylated p53 remains chromatin-associated and promotes a p53-dependent transcriptional program for cell cycle arrest rather than apoptosis. E4F1 and PCAF mediate mutually exclusive post-translational modifications of p53.\",\n      \"method\": \"In vitro ubiquitylation assay, mass spectrometry (site mapping), chromatin immunoprecipitation (ChIP), reporter assays, cell fate (apoptosis vs. growth arrest) analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro ubiquitylation reconstitution, site mapping by MS, ChIP, and functional cell fate readouts, published in Cell\",\n      \"pmids\": [\"17110336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"E4F1 interacts with BMI1 in hematopoietic cells (co-immunoprecipitation/pulldown), and genetic interaction between Bmi1 and E4f1 regulates cellular proliferation. RNAi-mediated knockdown of E4f1 rescues clonogenic and repopulating ability of Bmi1−/− hematopoietic cells, and this interaction is independent of INK4A/ARF and p53.\",\n      \"method\": \"Co-immunoprecipitation, RNA interference, hematopoietic transplantation assays, clonogenic assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — physical interaction confirmed by Co-IP plus in vivo genetic rescue experiment in transplantation model\",\n      \"pmids\": [\"16882984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Full-length E4F1 (p120E4F1), but not its truncated E1A-activated form (p50E4F1), directly interacts with the LIM-only protein FHL2 in vitro and in vivo in the nuclear compartment. This interaction inhibits E4F1's antiproliferative activity and its transcriptional repression, and reduces nuclear E4F1-p53 complexes. FHL2 nuclear accumulation upon UV light promotes endogenous E4F1-FHL2 complex formation.\",\n      \"method\": \"In vitro binding assay, co-immunoprecipitation, immunofluorescence (localization), reporter assays, UV-light stimulation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro binding plus reciprocal Co-IP in cells, functional repression assay, localization data, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"16652157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"E4F1 forms a complex with LANP (an INHAT corepressor) and modulates transcriptional repression. Ataxin 1 competes with E4F1 for LANP binding, thereby relieving the transcriptional repression induced by the LANP-E4F1 complex.\",\n      \"method\": \"Co-immunoprecipitation, transcriptional reporter assays, competition binding assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for complex, reporter assay for function, competition experiment, single lab\",\n      \"pmids\": [\"17557114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"E4F1 is essential for epidermal stem cell (ESC) maintenance and skin homeostasis in vivo. E4F1 conditional knockout in skin causes ESC pool exhaustion. Clonogenic potential of E4F1 KO ESCs is rescued by BMI1 overexpression or by Ink4a/Arf or p53 depletion, placing E4F1 upstream of the BMI1-Arf-p53 pathway in skin stem cells.\",\n      \"method\": \"Conditional knockout (Cre-loxP), ex vivo clonogenic assays, genetic epistasis (double knockout/overexpression rescue)\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with defined phenotype, epistasis rescue with multiple genetic combinations, in vivo and ex vivo readouts\",\n      \"pmids\": [\"21088222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"E4F1 inactivation in myeloid leukemic (histiocytic sarcoma) cells causes mitochondrial defects, increased reactive oxygen species (ROS) production, and massive autophagic cell death — effects observed in transformed cells but not normal primary macrophages. In vivo, genetic ablation of E4F1 in established tumors causes tumor regression.\",\n      \"method\": \"Cre-mediated conditional deletion in vivo (genetically engineered mouse model), ROS measurement, mitochondrial function assays, autophagy markers, shRNA knockdown in human cell lines\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic deletion with tumor regression, mechanistic mitochondrial/ROS assays, validated in human cell lines\",\n      \"pmids\": [\"21708927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"E4F1 physically interacts with hepatitis B virus protein HBx (co-precipitation in HCC cell lines). E4F1 depletion in HBV-expressing (but not HBV-negative) HCC cells induces hepatocyte vacuolation, increased autophagy, mitochondrial defects, and G1 cell cycle arrest; these effects are partially prevented by siRNA against HBx or p53.\",\n      \"method\": \"Co-immunoprecipitation/co-precipitation, RNA interference, flow cytometry (cell cycle), autophagy assays, metabolic profiling\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP for interaction, RNAi for functional readouts in HBV-dependent context, single lab with multiple readouts\",\n      \"pmids\": [\"24163401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"E4F1 directly controls transcription of Chek1 (CHK1) and genes involved in mitochondrial function. E4F1 inactivation in p53-deficient transformed cells causes CHK1-dependent checkpoint deficiency combined with mitochondrial dysfunction (increased ROS, energy stress, inhibition of de novo pyrimidine synthesis), leading to cell death. E4F1 ChIP-seq identified direct genomic targets in MEFs.\",\n      \"method\": \"ChIP-seq, RNA-seq (differential expression in E4F1 KO vs. WT), conditional knockout, ROS/metabolic assays, cell death assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP-seq establishes direct binding at Chek1 locus, combined with transcriptomic and metabolic functional readouts in KO model\",\n      \"pmids\": [\"25843721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"E4F1 physically interacts with CHK1 protein and protects it from degradation, functioning as a master regulator of CHK1. E4f1-deficient hematopoietic cells accumulate DNA damage, show S-phase and mitotic progression defects, and undergo apoptosis; ectopic Chek1 expression fully rescues these defects.\",\n      \"method\": \"Co-immunoprecipitation, conditional knockout (Cre-loxP in hematopoietic cells), DNA damage assays, cell cycle analysis, Chek1 overexpression rescue\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP plus full genetic rescue by Chek1 overexpression, in vivo knockout with defined phenotype, two independent labs (Sauvageau and Grote groups)\",\n      \"pmids\": [\"25843717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"E4F1 transcriptionally regulates four genes (Dlat, Dld, Mpc1, Slc25a19) required for pyruvate oxidation; E4F1 dysfunction results in ~80% decrease in pyruvate dehydrogenase (PDH) complex activity and altered pyruvate metabolism. Muscle-specific E4f1 knockout mice show low PDH activity, severe endurance defects, and chronic lactic acidemia.\",\n      \"method\": \"ChIP (direct binding to target gene promoters), conditional knockout (muscle-specific), PDH activity assay, metabolic profiling, pharmacological PDH stimulation and ketogenic diet rescue\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct ChIP binding plus enzymatic assay in KO tissue, pharmacological rescue, confirmed in two complementary PNAS studies (PMID 27621446 and 27621431)\",\n      \"pmids\": [\"27621446\", \"27621431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In keratinocytes, E4F1 transcriptionally regulates Dlat (encoding the E2 subunit of the PDH complex); E4f1 KO keratinocytes show impaired PDH activity, redirected glycolytic flux toward lactate, extracellular matrix remodeling, and loss of clonogenic potential. shRNA depletion of Dlat alone recapitulates these defects.\",\n      \"method\": \"Conditional knockout, PDH activity assay, metabolic flux assay (lactate measurement), shRNA knockdown, clonogenic assay\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with mechanistic PDH activity readout, shRNA validation of Dlat as key effector, multiple orthogonal metabolic assays\",\n      \"pmids\": [\"27621431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The 50 kDa form of E4F1 (p50E4F1) stably associates with E1A289R in vivo via the p50E4F1 transcription regulatory (TR) region and E1A CR3. E1A-mediated trans-activation requires the p50E4F1 TR region to be promoter-bound and depends on E1A CR3, CR1, and N-terminal domains. Multiple cellular proteins including TBP bind the p50E4F1 TR region in vitro.\",\n      \"method\": \"In vivo co-immunoprecipitation, in vitro binding assays, GAL4-fusion trans-activation assays, deletion mutagenesis\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — in vivo and in vitro binding with mutagenesis and functional trans-activation reporter assays, single lab\",\n      \"pmids\": [\"32535047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"E4F1 promotes DNA double-strand break (DSB) repair by: (1) being recruited to DNA breaks in a PARP-dependent manner; (2) promoting ATR/CHK1 signaling and DNA-end resection for homologous recombination; (3) binding to the chromatin remodeler BRG1/SMARCA4 and together with PARP-1 mediating BRG1 recruitment to DNA lesions.\",\n      \"method\": \"Live-cell imaging (recruitment to DNA breaks), PARP inhibitor treatment, co-immunoprecipitation (E4F1-BRG1), HR repair assays, DNA resection assays, CHK1 signaling assays\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Co-IP, live imaging, PARP-dependence, HR assays), mechanistic pathway placement, published in PNAS\",\n      \"pmids\": [\"33692124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"E4F1 directly interacts with p53 and both co-occupy the Stearoyl-CoA Desaturase-1 (SCD1) locus in adipocytes to regulate monounsaturated fatty acid synthesis. E4F1 deficiency in adipose tissue activates a p53-dependent transcriptional program controlling lipid metabolism; p53 inactivation or oleate supplementation partially restores adiposity in E4F1-deficient mice.\",\n      \"method\": \"ChIP (E4F1 and p53 co-occupancy at SCD1 locus), co-immunoprecipitation (E4F1-p53 interaction), conditional adipose-specific knockout, metabolic phenotyping, genetic epistasis (p53 inactivation rescue)\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct ChIP for co-occupancy at specific locus, Co-IP for interaction, in vivo KO with genetic rescue by p53 deletion, multiple orthogonal methods\",\n      \"pmids\": [\"34857760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In triple-negative breast cancer (TNBC) cells, E4F1 directly binds and regulates CHEK1 and two additional post-transcriptional regulators of the ATM/ATR-CHK1 axis: TTI2 (TTT complex, required for ATM/ATR folding/stability) and PPP5C (phosphatase regulating ATM/ATR signaling). E4F1 depletion downregulates CHK1, ATM, and ATR protein levels and signaling, causing failure to arrest in S-phase upon Gemcitabine treatment and sensitization to DNA-damaging agents.\",\n      \"method\": \"ChIP-seq, RNA-seq, E4F1 depletion (shRNA/siRNA), ATM/ATR/CHK1 signaling assays, PDX ChIP validation, drug sensitivity assays\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP-seq with RNA-seq intersection identifies direct targets, PDX in vivo validation, mechanistic signaling readouts, single lab\",\n      \"pmids\": [\"36012478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"E4F1 binds specifically to the -57A>C mutant TERT promoter and activates TERT transcription and telomerase activity. ZNF148 binds the wild-type TERT promoter and is a separate activating factor. Both were identified by a systematic proteomics screen (SILAC-based pull-down) and validated by ChIP in corresponding cell lines.\",\n      \"method\": \"SILAC-based proteomics pull-down screen, ChIP, TERT reporter assay, telomerase activity assay\",\n      \"journal\": \"Genome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomics pull-down discovery plus ChIP and functional reporter validation, single lab\",\n      \"pmids\": [\"37918959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In human cells, NF-κB/RelA cooperates with E4F1 to regulate dynamic expression of hsa-miR-210 during TLR immune responses, mirroring a conserved mechanism where Dorsal cooperates with Su(Hw) in Drosophila.\",\n      \"method\": \"Co-immunoprecipitation (RelA-E4F1), reporter assays, miR-210 expression assays upon TLR stimulation, knockdown experiments\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP for interaction plus functional reporter data in human cells, single lab\",\n      \"pmids\": [\"38742642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"E4F1 directly transcriptionally regulates both Dlat (PDH complex E2 subunit) and Elp3 (catalytic subunit of the Elongator complex) in neurons, coordinating AcCoA production by PDC and its utilization by Elongator to acetylate tRNAs at wobble uridine 34 (U34). This E4F1-mediated coordination ensures translation fidelity and neuronal cell survival during brain development. PDH-deficient (Leigh syndrome) cells show a perturbed PDC-to-ELP3 crosstalk.\",\n      \"method\": \"Conditional knockout (mouse), ChIP (direct promoter binding), primary neuronal cell assays, tRNA acetylation assay, translation fidelity assay, PDH-deficient patient cell analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct ChIP for dual target gene binding, in vivo KO with neuronal phenotype, biochemical tRNA acetylation and translation fidelity readouts, disease-relevant validation\",\n      \"pmids\": [\"39747033\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"E4F1 is a multifunctional GLI-Krüppel zinc-finger transcription factor and atypical E3 ubiquitin ligase that: (1) directly binds specific promoter elements to activate or repress transcription; (2) oligo-ubiquitylates p53 on hinge-region lysines (distinct from Hdm2 sites) to promote chromatin-associated p53-dependent cell cycle arrest rather than apoptosis; (3) transcriptionally controls a metabolic gene program encompassing the pyruvate dehydrogenase complex (Dlat, Dld, Mpc1, Slc25a19) and the Elongator complex (Elp3) to coordinate AcCoA production, tRNA acetylation, and translation fidelity; (4) regulates ATR/CHK1 signaling by directly driving CHEK1, TTI2, and PPP5C transcription and by physically protecting CHK1 from degradation; (5) is recruited to DNA double-strand breaks in a PARP-dependent manner, promotes DNA-end resection and homologous recombination via interaction with BRG1/SMARCA4; (6) interacts with multiple partners including BMI1, RASSF1A, FHL2, LANP/ataxin 1, and p53 to control stem cell maintenance, hematopoiesis, and cell fate decisions.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"E4F1 is a multifunctional GLI-Krüppel zinc-finger transcription factor that controls cell cycle progression, metabolism, and genome stability, and was originally defined as a direct, sequence-specific activator of the adenovirus E4 promoter whose DNA-binding is phosphorylation-dependent and inducible by E1A [#0, #1, #4]. The protein exists as a full-length form (p120E4F1) that represses transcription and an E1A-activated N-terminal 50 kDa fragment (p50E4F1) that stimulates it, the latter associating with E1A and basal factors such as TBP through its transcription regulatory region [#4, #18]. Beyond transcription, E4F1 acts as an atypical E3 ubiquitin ligase that oligo-ubiquitylates p53 on hinge-region lysines distinct from Hdm2 sites, retaining p53 on chromatin to drive a cell cycle arrest program rather than apoptosis [#7]. E4F1 is required for mitotic fidelity in vivo, where its loss causes chromosomal missegregation and embryonic lethality [#5]. It governs a transcriptional metabolic program by directly binding and activating pyruvate dehydrogenase complex genes (Dlat, Dld, Mpc1, Slc25a19), with loss causing collapsed PDH activity, lactic acidemia, and metabolic stress [#16, #17]; in neurons it co-regulates Dlat and the Elongator subunit Elp3 to couple AcCoA production to wobble-U34 tRNA acetylation and translation fidelity [#24]. E4F1 is also a master regulator of the ATR/CHK1 DNA-damage axis, directly driving CHEK1 (and the regulators TTI2 and PPP5C) transcription and physically binding CHK1 to protect it from degradation [#14, #15, #21], and it is recruited to double-strand breaks in a PARP-dependent manner to promote end resection and homologous recombination via the chromatin remodeler BRG1/SMARCA4 [#19]. Through physical interactions with BMI1, RASSF1A, FHL2, and p53, E4F1 integrates these activities into control of stem cell maintenance, hematopoiesis, and tumor cell survival [#6, #8, #9, #11, #20].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Established that E4F1 is a bona fide sequence-specific transcriptional activator, defining its founding molecular activity by showing its binding sites are required for E4 enhancer-driven transcription.\",\n      \"evidence\": \"In vitro transcription and DNA footprinting/gel-shift with binding-site mutants on the adenovirus E4 promoter\",\n      \"pmids\": [\"2956091\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the cellular gene targets beyond the viral E4 promoter\", \"No structural basis for sequence recognition\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Showed that E4F1 DNA-binding is post-translationally controlled by phosphorylation and identified the factor as a ~50 kDa polypeptide, linking its activity to signaling.\",\n      \"evidence\": \"Affinity purification with alkaline phosphatase treatment and in vitro DNA-binding reactivation by infected-cell extract\",\n      \"pmids\": [\"2545525\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible not identified\", \"Phosphorylation sites not mapped\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Distinguished E4F1 from ATF in binding specificity and complex stability and tied E4F1 specifically to E1A-dependent trans-activation, clarifying the functional element it controls.\",\n      \"evidence\": \"Comparative EMSA, site-specific mutagenesis, and cotransfection reporter assays\",\n      \"pmids\": [\"2169022\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of differential complex stability unresolved\", \"Cellular promoters obeying the same code unidentified\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Cloned the full-length 783-aa GLI-Krüppel protein and showed the 50 kDa species is an N-terminal fragment, revealing that full-length p120 represses while the p50 fragment activates, and that E1A differentially regulates the two forms.\",\n      \"evidence\": \"Expression cloning, immunological characterization, DNA-binding and reporter assays with phosphorylation analysis\",\n      \"pmids\": [\"9121437\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism generating the p50 fragment in cells not defined\", \"Domain map of repression vs activation incomplete\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrated an essential in vivo cell-cycle function: E4F1 is required for mitotic progression and chromosome segregation, with spindle localization, moving it from a viral cofactor to a core cell-cycle regulator.\",\n      \"evidence\": \"Knockout mouse with blastocyst analysis, spindle immunofluorescence, and flow cytometry\",\n      \"pmids\": [\"15226446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular targets driving the mitotic defect not identified\", \"Whether spindle localization reflects a non-transcriptional role unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified RASSF1A as a physical partner that cooperates with E4F1 to enforce G1/S arrest, placing E4F1 in a tumor-suppressor interaction network.\",\n      \"evidence\": \"Yeast two-hybrid, reciprocal pull-down and Co-IP, siRNA, and cell-cycle flow cytometry\",\n      \"pmids\": [\"14729613\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic consequence of the complex on E4F1 targets unclear\", \"Interaction domains not mapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealed an enzymatic activity beyond transcription: E4F1 oligo-ubiquitylates p53 at hinge lysines distinct from Hdm2, channeling p53 toward chromatin-associated arrest rather than apoptosis.\",\n      \"evidence\": \"In vitro ubiquitylation, MS site mapping, ChIP, and apoptosis-versus-arrest cell-fate readouts\",\n      \"pmids\": [\"17110336\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The E2 enzyme and full ligase complex not defined\", \"How ubiquitylation directs p53 to specific gene programs unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placed E4F1 in the BMI1 axis controlling hematopoietic proliferation independent of INK4A/ARF and p53, showing E4f1 knockdown rescues Bmi1-deficient stem cells.\",\n      \"evidence\": \"Co-IP, RNAi, and hematopoietic transplantation/clonogenic assays\",\n      \"pmids\": [\"16882984\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The p53/INK4A-independent effector pathway not identified\", \"Direct genomic targets in hematopoietic cells unmapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified FHL2 as a nuclear inhibitor of full-length E4F1 that dampens its antiproliferative and repressive activity and reduces E4F1-p53 complexes in response to UV.\",\n      \"evidence\": \"In vitro binding, reciprocal Co-IP, immunofluorescence, and repression reporter assays\",\n      \"pmids\": [\"16652157\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FHL2 affects E4F1 ligase activity not tested\", \"Physiological signals beyond UV not explored\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed E4F1 acts as a corepressor partner of LANP/INHAT, with ataxin-1 competing for LANP to relieve repression, linking E4F1 to chromatin-based repression machinery.\",\n      \"evidence\": \"Co-IP, competition binding, and transcriptional reporter assays\",\n      \"pmids\": [\"17557114\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous target genes of the LANP-E4F1 complex not defined\", \"Single-lab finding without independent reconstitution\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established E4F1 as essential for epidermal stem cell maintenance and positioned it upstream of the BMI1-Arf-p53 pathway in skin homeostasis.\",\n      \"evidence\": \"Conditional skin knockout, ex vivo clonogenic assays, and genetic epistasis rescues\",\n      \"pmids\": [\"21088222\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets in stem cells not identified\", \"Mechanism linking E4F1 to the BMI1-Arf-p53 axis unresolved at the gene level\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Revealed a selective dependency of transformed cells on E4F1: its loss triggers mitochondrial dysfunction, ROS, and autophagic death in tumor cells but not normal macrophages, with tumor regression in vivo.\",\n      \"evidence\": \"Conditional deletion in a mouse tumor model, ROS and mitochondrial assays, and shRNA in human lines\",\n      \"pmids\": [\"21708927\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The transcriptional targets producing the mitochondrial defect not yet defined here\", \"Basis of tumor-selective dependence unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended the tumor-selective dependency to HBV-positive hepatocellular carcinoma via an E4F1-HBx interaction, with E4F1 loss causing autophagy, mitochondrial defects, and G1 arrest in an HBV/p53-dependent manner.\",\n      \"evidence\": \"Co-precipitation, RNAi, cell-cycle and autophagy assays in HCC lines\",\n      \"pmids\": [\"24163401\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of the HBx interaction on E4F1 activity not defined\", \"Single-lab, context-restricted finding\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected E4F1 to the DNA-damage checkpoint by both directly transcribing Chek1 and protecting CHK1 protein from degradation, with Chek1 re-expression fully rescuing E4f1-loss phenotypes.\",\n      \"evidence\": \"ChIP-seq, conditional knockout, Co-IP, DNA-damage/cell-cycle assays, and Chek1 overexpression rescue (two independent labs)\",\n      \"pmids\": [\"25843721\", \"25843717\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which E4F1 stabilizes CHK1 protein not defined\", \"Coupling between the checkpoint and metabolic roles unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined E4F1 as a direct transcriptional controller of the pyruvate-oxidation program (Dlat, Dld, Mpc1, Slc25a19), establishing its central role in metabolic gene regulation with in vivo PDH and endurance phenotypes.\",\n      \"evidence\": \"ChIP, muscle- and keratinocyte-specific knockouts, PDH activity and metabolic flux assays, shRNA of Dlat, and dietary/pharmacological rescue\",\n      \"pmids\": [\"27621446\", \"27621431\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How metabolic and checkpoint target programs are co-selected unresolved\", \"Upstream signals tuning this program not identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed E4F1 is recruited to double-strand breaks in a PARP-dependent manner and promotes end resection and homologous recombination through BRG1/SMARCA4, adding a direct chromatin-level repair function.\",\n      \"evidence\": \"Live-cell imaging of recruitment, PARP inhibition, Co-IP with BRG1, and HR/resection assays\",\n      \"pmids\": [\"33692124\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether transcriptional and recruitment roles act in parallel at breaks unresolved\", \"Residues mediating PARP-dependent recruitment not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated direct E4F1-p53 co-occupancy at the SCD1 locus controlling monounsaturated fatty acid synthesis in adipose tissue, broadening the metabolic program to lipid metabolism with p53-dependent rescue.\",\n      \"evidence\": \"ChIP co-occupancy, Co-IP, adipose-specific knockout, metabolic phenotyping, and p53-deletion/oleate rescue\",\n      \"pmids\": [\"34857760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether E4F1 ubiquitylation of p53 contributes at this locus untested\", \"Tissue specificity of the SCD1 program unexplained\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Generalized the ATR/CHK1 axis control to human TNBC, showing E4F1 directly regulates CHEK1, TTI2, and PPP5C and that its loss collapses ATM/ATR/CHK1 signaling and sensitizes cells to DNA-damaging agents.\",\n      \"evidence\": \"ChIP-seq, RNA-seq, E4F1 depletion, signaling assays, PDX ChIP validation, and drug-sensitivity assays\",\n      \"pmids\": [\"36012478\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single-lab finding\", \"Relative contribution of each target to checkpoint failure not dissected\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified E4F1 as a mutation-specific activator of the -57A>C TERT promoter, implicating it in telomerase reactivation in cancer.\",\n      \"evidence\": \"SILAC pull-down proteomics screen, ChIP, TERT reporter, and telomerase activity assays\",\n      \"pmids\": [\"37918959\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Why E4F1 selectively binds the mutant promoter not defined\", \"Single-lab proteomics-based discovery\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed E4F1 cooperates with NF-κB/RelA to control dynamic miR-210 expression during TLR immune responses, extending its transcriptional partnerships to innate immunity.\",\n      \"evidence\": \"RelA-E4F1 Co-IP, reporter assays, and miR-210 expression upon TLR stimulation with knockdowns\",\n      \"pmids\": [\"38742642\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding of E4F1 at the miR-210 locus in human cells not fully resolved\", \"Physiological immune consequence untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealed that E4F1 coordinates AcCoA production (via Dlat/PDC) with its utilization by the Elongator subunit Elp3 for wobble-U34 tRNA acetylation, linking metabolism to translation fidelity and neuronal survival.\",\n      \"evidence\": \"Conditional knockout, ChIP at Dlat and Elp3, tRNA acetylation and translation-fidelity assays, and PDH-deficient patient cell analysis\",\n      \"pmids\": [\"39747033\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How E4F1 simultaneously sets producer and consumer gene levels mechanistically unresolved\", \"Generality of the PDC-Elongator crosstalk beyond neurons untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how E4F1 integrates its dual roles as a transcription factor and an atypical p53 E3 ligase, and what signals partition it between metabolic, checkpoint, and DNA-repair programs in a given cell type.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model coordinating DNA-binding and ligase domains\", \"Mechanism stabilizing CHK1 protein undefined\", \"Rules selecting metabolic vs checkpoint target genes unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 4]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 4, 14, 16, 24]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [7, 19]},\n      {\"term_id\": \"GO:0005819\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 4, 14, 16, 24]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [5, 6, 15]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [19, 21]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [14, 15, 21]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [16, 17, 20, 24]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TP53\", \"BMI1\", \"RASSF1A\", \"FHL2\", \"CHEK1\", \"SMARCA4\", \"RELA\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}